Showing 133 to 144 of 218 results
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
Progress
48% Bias Score
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people in Europe revealed that closely following the Mediterranean diet reduces obesity-related cancer risk by 6%, regardless of BMI, suggesting other health benefits contribute to cancer prevention.
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people in Europe revealed that closely following the Mediterranean diet reduces obesity-related cancer risk by 6%, regardless of BMI, suggesting other health benefits contribute to cancer prevention.
Progress
52% Bias Score
European Life Expectancy Slowdown Linked to Lifestyle Factors
A new study in The Lancet Public Health reveals a slowdown in Europe's life expectancy increase since 2011, attributed to rising obesity, inactivity, and poor diet, with the COVID-19 pandemic worsening the situation; this deceleration varies across countries, with the UK experiencing significant cha...
European Life Expectancy Slowdown Linked to Lifestyle Factors
A new study in The Lancet Public Health reveals a slowdown in Europe's life expectancy increase since 2011, attributed to rising obesity, inactivity, and poor diet, with the COVID-19 pandemic worsening the situation; this deceleration varies across countries, with the UK experiencing significant cha...
Progress
28% Bias Score
Alcohol Consumption Significantly Increases Liver Damage Risk in Individuals with Pre-existing Conditions
A study found that drinking alcohol increases the risk of serious liver damage significantly more for people with a large belly, diabetes, or high blood pressure; researchers suggest that this is a serious concern given the high prevalence of these conditions in the US and the increased consumption ...
Alcohol Consumption Significantly Increases Liver Damage Risk in Individuals with Pre-existing Conditions
A study found that drinking alcohol increases the risk of serious liver damage significantly more for people with a large belly, diabetes, or high blood pressure; researchers suggest that this is a serious concern given the high prevalence of these conditions in the US and the increased consumption ...
Progress
52% Bias Score
High Ultra-Processed Food Consumption in American Diet Linked to Serious Health Risks
More than half of the average American diet consists of ultra-processed foods, which are high in sodium and saturated fat and low in nutrients, significantly contributing to health problems such as cardiovascular disease, obesity, and colorectal cancer, according to registered dietitian Jinan Banna ...
High Ultra-Processed Food Consumption in American Diet Linked to Serious Health Risks
More than half of the average American diet consists of ultra-processed foods, which are high in sodium and saturated fat and low in nutrients, significantly contributing to health problems such as cardiovascular disease, obesity, and colorectal cancer, according to registered dietitian Jinan Banna ...
Progress
48% Bias Score
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Progress
48% Bias Score
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people found that closely following the Mediterranean diet reduced the risk of obesity-related cancers by approximately 6%, regardless of BMI, potentially due to factors beyond weight loss such as reduced inflammation, suggesting its significant role in cancer prevention ...
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people found that closely following the Mediterranean diet reduced the risk of obesity-related cancers by approximately 6%, regardless of BMI, potentially due to factors beyond weight loss such as reduced inflammation, suggesting its significant role in cancer prevention ...
Progress
44% Bias Score
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
Progress
40% Bias Score
Alcohol Consumption Significantly Increases Liver Damage Risk in Individuals with Preexisting Conditions
A recent study found that drinking alcohol while having a large belly, diabetes, or high blood pressure more than doubles the risk of serious liver damage; this is especially concerning given that nearly half of all Americans have high blood pressure, more than 1 in 3 have prediabetes, and about 40%...
Alcohol Consumption Significantly Increases Liver Damage Risk in Individuals with Preexisting Conditions
A recent study found that drinking alcohol while having a large belly, diabetes, or high blood pressure more than doubles the risk of serious liver damage; this is especially concerning given that nearly half of all Americans have high blood pressure, more than 1 in 3 have prediabetes, and about 40%...
Progress
40% Bias Score
Record High Diabetes and Prediabetes Rates in the UK
A new report reveals that 12.2 million UK adults—one in five—have diabetes or prediabetes, driven by obesity and unhealthy diets, prompting calls for government intervention to improve the nation's health.
Record High Diabetes and Prediabetes Rates in the UK
A new report reveals that 12.2 million UK adults—one in five—have diabetes or prediabetes, driven by obesity and unhealthy diets, prompting calls for government intervention to improve the nation's health.
Progress
52% Bias Score
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Progress
36% Bias Score
Showing 133 to 144 of 218 results